I've edited slightly to make this more readable - 'lizbeth
Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study.
Abstract No:
532
Attend this session at the
2014 ASCO Annual Meeting!
Session: Breast Cancer - HER2/ER
Type: Poster Highlights Session
Time 1: Sunday June 1, 8:00 AM to 11:00 AM
Location 1: E354b
Time 2: Sunday June 1, 11:30 AM to 12:45 PM
Location 2: E Arie Crown Theater
Author(s): Ivana Sestak, Yi Zhang, Catherine A. Schnabel, Brock Schroeder, Mark Erlander, Paul E. Goss, Jack M. Cuzick, Mitchell Dowsett, Dennis Sgroi; Queen Mary, University of London, London, United Kingdom; bioTheranostics, Inc., San Diego, CA; Trovagene, San Diego, CA; Massachusetts General Hospital Cancer Center, Boston, MA; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Massachusetts General Hospital, The Avon Foundation, Boston, MA
Abstract Disclosures
Abstract:
Background: Breast cancer index (BCI) is a genomic signature that significantly predicts risk of both early (0-5y) and late (5-10y) distant recurrence (DR) in HR+, LN- breast cancer. Previous results from the TransATAC study showed that both
breast cancer index (BCI) and Oncotype Dx RS added significant prognostic information for 10y DR risk. Here, pre-defined risk stratification with
breast cancer index (BCI) vs
recurrence score (RS) and its potential clinical impact were comparatively evaluated.
Methods: 665 HR+, LN- patients were examined. BCI and
recurrence score (RS) risk groups were determined using pre-defined clinical cut-points. Kaplan-Meier estimates of 10y risk of DR and log-rank tests were used to examine cross-stratification between
breast cancer index (BCI) and
recurrence score (RS). Likelihood Ratio (LR) tests were used to quantitate relative prognostic information beyond CTS.
Results: breast cancer index (BCI) re-stratification of the RS-Intermediate (RS-I) and RS-Low (RS-L) groups significantly impacted risk of 10y DR (P=0.003 and P<0.001), whereas RS did not significantly re-stratify BCI risk prediction (Table).
breast cancer index (BCI) identified a small subset (20 pts in RS-L) with a high risk of DR (23.3%). Furthermore,
breast cancer index (BCI) identified a large (95 pts in RS-I) and smaller (34 pts in RS-I) subset with 7.1% and 27.8% 10y DR risk, respectively. BCI added significant prognostic information beyond CTS+ RS (p=0.0009), whereas
recurrence score (RS) did not provide additional prognostic information beyond CTS+
breast cancer index (BCI) (p=0.1).
Conclusions: In this retrospective analysis evaluating individualized risk stratification,
breast cancer index (BCI) identified subsets of RS-L and RS-I LN- patients with significant and clinically distinct rates of DR.
Breast cancer index (BCI) identified a small subset of RS-L and RS-I LN- patients that would potentially benefit from additional therapy.
Risk stratification and 10-year distant recurrence rates (%). No. of patients
| BCI risk groups
|
| Low | Inter | High | Total | P value |
| RS risk groups | Low | 283
(3.9%) | 85
(12.2%) | 20
(23.3%) | 388
(6.6%) | <0.001 |
| Inter | 95
(7.1%) | 49
(24.3%) | 34
(27.8%) | 178
(15.8%) | 0.003 |
| High | 12
(10%) | 32
(25.4%) | 55
(31.5%) | 99
(26.9%) | 0.2 |
| Total | 390
(4.8%) | 166
(18.3%) | 109
(29.0%) | 665 |
|
| P value | 0.4 | 0.07 | 0.6 |
|